<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643470</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-217</org_study_id>
    <nct_id>NCT04643470</nct_id>
  </id_info>
  <brief_title>Zanubrutinib in Participants With Active Proliferative Lupus Nephritis</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Zanubrutinib in Patients With Active Proliferative Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of zanubrutinib added to&#xD;
      standard of care as measured by complete renal response for participants with active&#xD;
      proliferative lupus nephritis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with complete renal response</measure>
    <time_frame>Week 49 Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving complete renal response</measure>
    <time_frame>Week 25 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving partial renal response</measure>
    <time_frame>Week 25 Day 1 and Week 49 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving overall renal response</measure>
    <time_frame>Week 25 Day 1 and Week 49 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first complete renal response</measure>
    <time_frame>Up to Week 73 Day 1</time_frame>
    <description>The time from the date of randomization to the date of the first complete renal response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first partial renal response</measure>
    <time_frame>Up to Week 73 Day 1</time_frame>
    <description>The time from the date of randomization to the date of the first partial renal response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score</measure>
    <time_frame>Week 25 Day 1 and Week 49 Day 1</time_frame>
    <description>SLEDAI-2K score is an systemic lupus erythematosus (SLE) activity index based on the presence of 24 features in 9 organ systems which ranges from 0 - 105, with higher scores indicating more severe features in participants in the past 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration time curve (AUC) of zanubrutinib</measure>
    <time_frame>Week 1 Day 1 and Week 5 Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Zanubrutinib Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive zanubrutinib 40 mg twice daily (BID) for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zanubrutinib High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive zanubrutinib 160 mg twice daily (BID) for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zanubrutinib Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive zanubrutinib 160 mg once daily (QD) for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo to match zanubrutinib for 72 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Zanubrutinib High Dose</arm_group_label>
    <arm_group_label>Zanubrutinib Low Dose</arm_group_label>
    <arm_group_label>Zanubrutinib Medium Dose</arm_group_label>
    <other_name>BGB-3111</other_name>
    <other_name>Brukinsa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match zanubrutinib</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of SLE according to the Systemic Lupus International Collaborating&#xD;
             Clinics 2012 criteria.&#xD;
&#xD;
          2. ISN/RPS 2003 Class III/IV lupus nephritis [Type III(A), III (A+C), IV (A), and IV&#xD;
             (A+C)], with or without Class V, as confirmed by a renal biopsy.&#xD;
&#xD;
          3. Positive antinuclear antibodies, positive anti-dsDNA autoantibody, and/or positive&#xD;
             anti Smith autoantibody at screening&#xD;
&#xD;
          4. Has 24-hour urine protein excretion &gt; 1.0 g at screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria related to systemic lupus erythematous and other diseases:&#xD;
&#xD;
          1. Glomerulonephritis caused by reasons other than systemic lupus erythematous.&#xD;
&#xD;
          2. Sclerosis in &gt;50% of glomeruli on renal biopsy.&#xD;
&#xD;
          3. Any other inflammatory diseases that might confound the assessments of efficacy,&#xD;
             including but not limited to rheumatoid arthritis, myositis, vasculitis, or&#xD;
             overlapping syndrome.&#xD;
&#xD;
          4. Severe extrarenal SLE, including but not limited to pulmonary arterial hypertension,&#xD;
             severe myocarditis, severe central nervous system lupus (such as neuropsychiatric SLE,&#xD;
             seizures, psychosis, transverse myelitis, central nervous system vasculitis and optic&#xD;
             neuritis), etc.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhen Yao, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

